Prostate high dose -rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy

RADIOTHERAPY AND ONCOLOGY

ELSEVIER IRELAND LTD

1. AbbVie-CARO Uro-Oncologic Radiation Award (ACURA), from the Canadian Association of Radiation Oncologists